Emerging landscape of COVID-19 vaccines in India on July 31: Bharat Biotech, Serum Institute, Zydus in charge

More than a dozen Indian companies are partnering with other companies and institutes to bring a preventive vaccine to global markets by 2021.

Three Indian companies have started testing vaccines for COVID-19 in humans in rapid trials. However, there are more than a dozen Indian companies in partnership with other companies and institutes – in India and abroad – to bring a functional vaccine against the SARS-CoV-2 coronavirus to global markets.

Advertisement

Here is an overview of different candidates from Indian companies who declared their progress (or intention) to develop a vaccine against the new coronavirus, on July 31, 2020.

Bharat Biotech

Bharat Biotech, in partnership with the National Institute of Virology, started recruiting volunteers to Phase 1 tests test the safety and neutralize antibodies of its candidate for the Covaxin vaccine (BBV152) in 375 healthy volunteers as of July 13.

Based on how volunteers respond in these trials, Bharat Biotech plans to continue with a multicenter, randomized, double-blind Phase 2 study with 750 volunteers to see how safe and effective the BBC152 vaccine is in a larger group.

Advertisement

Bharat Biotech is also collaborating with Thomas Jefferson University to develop a disabled recombinant rabies virus containing the spike protein against SARS-CoV-2. With support from the Biotechnology Department, Bharat Biotech plans to enter human trials of the vaccine by December 2020.

Serum Institute of India

The Serum Institute of India is currently conducting a randomized, double-blind study of a Recombinant BCG vaccine (VPM1002) for severe cases of coronavirus infection. The vaccine is an additional development of the 100-year-old Bacillus Calmette-Guérin (BCG) vaccine, still widely used in the treatment of tuberculosis. In the course Phase 3 tests in 5,946 volunteers, the Serum Institute is testing whether the vaccine reduces the severity of COVID-19 in high-risk patients.

Advertisement

The Serum Institute also said it will start testing the Oxford-AstraZeneca vaccine (AZD1222) candidate in India soon. Received a ban on Indian regulators by their testing protocol this week, and is expected to run a revised version by the Indian regulator (CDSCO) within a few days. After promising results in mid-July Since the first tests of the Oxford-AstraZeneca experimental vaccine, Serum has announced that manufacture a billion doses of the vaccine after getting the necessary approvals.

The Serum Institute, in partnership with Codagenix, based in the USA, is developing a living candidate for the attenuated vaccine COVID-19 CDX-005, which is in pre-clinical trials in July 2020.

An illustration of COVAXIN, the vaccine candidate for COVID-19, developed by Bharath Biotech. Image: Bharath Biotech

Advertisement

Zydus Cadila

Zydus Cadila Healthcare, supported by the Department of Biotechnology (DBT), started recruiting for its phase 1/2 clinical trials July 13 to test the safety and effectiveness of its DNA Plasmid ZyCoV-D vaccine candidate in 1,048 volunteers. In the pre-clinical phase, ZyCoV-D produced a strong immune response in several animal species including mice, rats, guinea pigs and rabbits, and did not raise safety concerns.

Advertisement

One second measles vaccine currently a candidate for Zydus' COVID-19 pre-clinical trials.

Panacea Biotec

Panacea Biotec entered into a partnership with Refana, based in the USA, to develop, manufacture and distribute a candidate for the COVID-19 vaccine globally until next year. The Irish-based joint venture is working on a vaccine inactivated by SARS-CoV-2, adding a interview with Reuters that the vaccine is currently in animals pre-clinical trials, With human testing phase 1 likely starting only after September 2020.

The goal is to produce 500 million doses in 2021 and a billion doses vaccine candidate in 2022, according to the report.

Indian Immunologicals

Indian Immunologicals and Australia's Griffith University have partnered to develop a potential candidate for the COVID-19 vaccine that could provide "lasting protection with a single dose,"as per April press release.

The company intends to assume live attenuated vaccine once developed, and conduct clinical trials under Indian regulators in a phased manner. Vaccine development is currently in preclinical stages, according to WHO recommendations. vaccine tracker as on July 31st.

Emerging landscape of COVID19 vaccines in India from July 31 Bharat Biotech Serum Institute Zydus in charge

The J&J vaccine, which enters Phase 2 testing in late July, after successfully protecting the COVID monkeys with a single shot. Image: JnJ

Mynvax

The startup incubated by the Indian Institute of Science Mynvax received funding and support from Bill and Melinda Gates Foundation to develop a series of recombinant subunit vaccines for SARS-CoV-2. The vaccine will be targeted mainly at the groups most at risk for COVID-19 (health professionals, the elderly and people with comorbid conditions).

Mynvax said in a May update that pre-clinical selection and testing has been completed for many candidates, with more tests being selected "in the coming months". Mynvax also requested R $ 15 million in funding from the Biotechnology Industry Research Assistance Council (BIRAC) to expand and manufacture successful candidates.

Other Indian companies in preclinical trials

And biological was also supported by Bill and Melinda Gates Foundation. The company is developing a protein subunit vaccine using the peak protein portion of the SARS-COV-2 virus. The vaccine candidate is in pre-clinical testing on July 31, 2020.

Aurobindo Pharma based in Hyderabad is also currently conducting preclinical tests for its SARS-CoV-2 replicating viral vector vaccine.

Premas Biotech based on Gurugram is supposedly working on a triple antigen vaccine candidate and successfully identified three antigens with which to develop independent candidates for recombinant SARS-CoV-2 vaccine.

Based in Ahmedabad Hester Biosciences in colaboration with IIT-Guwahati is supposedly to develop a vaccine against COVID-19 using an avian recombinant paramyxovirus vector. Mainly an animal health company and the second largest manufacturer of poultry vaccines, this will be the company's first foray into human vaccines.

Gujarat Biotechnology Research Center (GBRC) has in partnership with Neuberg Supratech, a pathology laboratory based in Ahmedabad, under Neuberg Diagnostics, to develop vaccines and COVID-19 recombinant diagnoses.

Find the latest and future technology gadgets online at Tech2 gadgets. Get tech news, reviews, and gadget ratings. Popular gadgets, including laptop, tablet and mobile specs, features, pricing and comparison.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *